Prospects for prophylactic hepatitis C vaccines based on virus-like particles

Autor: Philippe Roingeard, Elodie Beaumont
Přispěvatelé: Roingeard, Philippe, Virus, pseudo-virus: Morphogénèse et Antigénicité, Université de Tours (UT)-EA3856, Work on prophylactic hepatitis C vaccination strategies in our laboratory is currently supported by the Institut Mérieux, the Emergence program of the Agence Nationale pour la Recherche (ANR, France), the FEDER (Fonds Européens de Développements en Region - Région Centre, France) and the Cluster de Recherche en Infectiologie (Région Centre, France).
Rok vydání: 2013
Předmět:
liver diseases
Hepacivirus
Hepatitis C virus
Immunology
Drug Evaluation
Preclinical
viral hepatitis
medicine.disease_cause
immune response
Virus
virus-like particle
03 medical and health sciences
0302 clinical medicine
MESH: Drug Discovery
Virus-like particle
MESH: Viral Vaccines
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Drug Discovery
medicine
Humans
Immunology and Allergy
MESH: Hepacivirus
Vaccines
Virus-Like Particle
MESH: Vaccines
Virus-Like Particle
030304 developmental biology
MESH: Hepatitis C
Pharmacology
0303 health sciences
MESH: Humans
biology
business.industry
Viral Vaccine
Viral Vaccines
Hepatitis C
medicine.disease
biology.organism_classification
Virology
3. Good health
Vaccination
[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Commentary
MESH: Drug Evaluation
Preclinical
030211 gastroenterology & hepatology
preventive vaccination
business
Viral hepatitis
Zdroj: Human Vaccines & Immunotherapeutics
Human Vaccines & Immunotherapeutics, Taylor & Francis, 2013, 9 (5), pp.1112-8. ⟨10.4161/hv.23900⟩
ISSN: 2164-554X
2164-5515
DOI: 10.4161/hv.23900
Popis: International audience; Given the global prevalence and long-term complications of chronic hepatitis C virus (HCV) infection, HCV constitutes one of the greatest challenges to human health of this decade. Considerable efforts have focused on the development of new effective treatments, but about three to four million individuals become infected each year, adding to the world reservoir of HCV infection. The development of a prophylactic vaccine against hepatitis C virus has thus become an important medical priority. Only a few vaccine candidates have progressed to the clinical phase, and published data on both the efficacy and safety of these vaccines are limited, due to many scientific, logistic and bioethic challenges. Fortunately, new innovative vaccine formulations, modes of vaccination and delivery technologies have been developed in recent years. Several preclinical trials of virus-like particle (VLP)-based vaccination strategies are currently underway and have already generated very promising results. In this commentary, we consider the current state of prophylactic HCV vaccines, the hurdles to be overcome in the future and the various VLP-based vaccination approaches currently being developed.
Databáze: OpenAIRE
Externí odkaz: